Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | RBP4 | P02753 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17559397 | 0.98 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPTHPGDGAA | |
| SCHEMBL14422387 | 0.86 | ALDH1A1 (0.66) | ALDH1A1KMT2AMAPTHPGDGAA | |
| SCHEMBL17559469 | 0.86 | HPGD (0.61) | ALDH1A1KMT2AMAPTHPGDGAA | |
| SCHEMBL9133746 | 0.85 | ALDH1A1 (0.64) | ALDH1A1KMT2AHPGDRBP4POLB | |
| Lithium Ion SCHEMBL17559395 | 0.83 | ALDH1A1 (0.51) | ALDH1A1KMT2AMAPTHPGDGAA | |
| SCHEMBL3900270 | 0.82 | KMT2A (0.70) | ALDH1A1KMT2AMAPTHPGDGAA | |
| SCHEMBL14980308 | 0.80 | POLB (0.72) | KMT2AHPGDCYP2C19POLBMEN1 | |
| SCHEMBL17573009 | 0.80 | HSP90AA1 (0.54) | ALDH1A1KMT2AHPGDRBP4POLB | |
| SCHEMBL17559436 | 0.79 | HSP90AA1 (0.53) | ALDH1A1KMT2AHPGDRBP4POLB | |
| SCHEMBL8658563 | 0.78 | HPGD (0.68) | ALDH1A1KMT2AHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-19 | — | — | US | disclosed |
| WO-2016034673-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | ALDH1A1 4190/4885KMT2A 38/4885MAPT 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.